Efficacy and Atypicals: It’s Hand-to-Hand Combat
The Carlat Psychiatry Report, Volume 2, Number 2, February 2004
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Things were bound to get ugly. The total market for antipsychotics is $10 billion, there are five very similar atypicals jockeying for an extra nibble of that huge pie, and each atypical is backed by an aggressive pharmaceutical firm. You do the math.